横浜薬科大学 · 臨床薬学科

研究キーワード薬物・内因性化合物の体内動態解析を基にした、ヒトにおける薬効・副作用の個人差を予測するための研究・Physiologically・based・pharmacokinetic・modelling・Pharmacokinetics・Futatsugi・Toshimoto

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• 1. Sato M, Toshimoto K, Tomaru A, Yoshikado T , Tanaka Y, Hisaka A, Lee W, Sugiyama Y. Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake as A Major Contributor to Its Nonlinear Pharmacokinetics. Drug Metab Dispos. 2018 Feb 23. pii: dmd.117.078972. doi: 10.1124/dmd.117.078972. [Epub ahead of print]2018
• 2. Futatsugi A, Toshimoto K, Yoshikado T , Sugiyama Y, Kato Y. Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin. Drug Metab Dispos. 2018 Feb 12. pii: dmd.117.078816. doi: 10.1124/dmd.117.078816. [Epub ahead of print]2018
• 4. Yoshikado T , Maeda K, Kusuhara H, Furihata K, Sugiyama Y. Quantitative analyses of the influence of parameters governing rate-determining process of hepatic elimination of drugs on the magnitudes of drug-drug interactions via hepatic OATPs and CYP3A using physiologically-based pharmacokinetic models. J Pharm Sci 106:2739-50 (2017)2017
• 8. Kashihara Y, Ieiri I, Yoshikado T , Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Kanda E, Izumi N, Kusuhara H, Sugiyama Y. Small-dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of Five Probes for OATP2B1 and BCRP. J Pharm Sci 106:2688-94 (2017)2017

• 公式プロフィール